Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.580
+0.120 (8.22%)
At close: Aug 1, 2025, 4:00 PM
1.610
+0.030 (1.90%)
After-hours: Aug 1, 2025, 4:58 PM EDT
Blueprint Medicines Stock Forecast
PLRX's stock price has decreased by -88.96% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts that cover Blueprint Medicines stock have a consensus rating of "Hold" and an average price target of $9.79, which forecasts a 519.62% increase in the stock price over the next year. The lowest target is $1.50 and the highest is $45.
Price Target: $9.79 (+519.62%)
Analyst Consensus: Hold
* Price targets were last updated on Mar 4, 2025.
Analyst Ratings
The average analyst rating for Blueprint Medicines stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 9 | 9 | 9 | 9 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 4, 2025 |
| Citigroup | Citigroup | Hold Maintains $4 → $1.5 | Hold | Maintains | $4 → $1.5 | -5.06% | Mar 4, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +89.87% | Mar 4, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Mar 4, 2025 |
Financial Forecast
Revenue This Year
2.27M
Revenue Next Year
1.70M
from 2.27M
Decreased by -25.01%
EPS This Year
-2.59
from -3.47
EPS Next Year
-1.95
from -2.59
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 15.8M | 199.8M | ||
| Avg | 2.3M | 1.7M | 29.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 594.8% | 11,652.4% | ||
| Avg | - | -25.0% | 1,659.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.18 | -0.75 | -0.37 | ||
| Avg | -2.59 | -1.95 | -1.08 | ||
| Low | -3.07 | -2.69 | -2.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.